By: Benzinga
UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ISIS Pharmaceuticals
In a report published Wednesday, Jefferies reiterated its Underperform rating on ISIS Pharmaceuticals (NASDAQ: ISIS ), and slightly raised its price target from $6.50 to $7.00. Jefferies noted, “Kynamro (mipomersen) approval for HoFH validates ISIS' antisense technology platform from a regulatory standpoint - positive. However, we continue to view Kynamro's
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here